Across TCGA pan-cancer cohorts, GLMN Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLMN data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GLMN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GLMN expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
HNSC, STAD, and UCEC are the cancer types where GLMN Mutation most reproducibly stratifies survival.